Multinational operator Clever Leaves has been granted EU-GMP for the manufacturing of cannabis dried flower as an active pharmaceutical ingredient and as finished product.
The EU-GMP certification is required for the registration and marketing of medicinal cannabis products in Europe.
The company has stated that the certification represents an important step toward broadening its ability to reach European patients with its own products, and will bolster its commitment to supporting other cannabis companies in the region by providing a platform for achieving the necessary GMP standard for expansion into the European market.
Read more: Clever Leaves announces first export of cannabis flower to Israel
Andres Fajardo, Clever Leaves’ CEO, commented: “Receiving this certification and completing the rigorous process is an honor and accomplishment for Clever Leaves, from the initial design of the installations, through the qualification and validation of all equipment and processes, to the integration of the new unit’s quality procedures into the existing quality system of Clever Leaves Portugal.
“The fact that we were able to meet the highest of pharmaceutical standards in less than 10 months after completion of the new facility is a huge milestone for Clever Leaves and we could not be more proud of our team for their exemplary work.”
Clever Leaves is one of few cannabis companies in Portugal to receive EU-GMP certification for post-harvest cannabis flower in the format of API and finished product.
This certification opens up new revenue streams while consolidating existing ones in the EMEA and Pacific regions.
